David R. Margrave serves as Chief Financial Officer of Lantern Pharma Inc., a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process. He has served as a senior executive in the life science sector for the last two decades, including previous service as President of BioNumerik Pharmaceuticals, Inc. Prior to joining BioNumerik, Mr. Margrave was a Partner in the technology group at Andrews & Kurth LLP, a national law firm. Mr. Margrave also serves as Chairman and a Director of The Texas Healthcare and Bioscience Institute (THBI), and Chairman and a Board Member of the State of Texas Product Development & Small Business Incubator Board. He is a past Director of the Texas Technology Transfer Association and a former Board Member of the Stanford Associates Board of Governors. Mr. Margrave received a Bachelor of Arts and Science degree from Stanford University and a J.D. degree from The University of Texas School of Law.